Household & Personal Products

Clorox’s Q2 earnings dip: revenue flat, EPS down, investors pull back—learn how the household‑cleaning brand is navigating margin pressure and market shifts.

Clorox’s Q2 earnings miss shows margin squeeze, regulatory pressure, and price‑war risks, yet highlights eco‑friendly growth and data‑driven pricing as key recovery paths.

Colgate‑Palmolive’s analyst rally hinges on solid cash flow, sustainable packaging moves and new probiotic products, but regulatory, supply‑chain and competitive risks loom.

Clorox institutional trades show a balanced mix of buying and selling—hedge funds and asset managers stay active yet unchanged on value, keeping the stock steady within its 52‑week range.

Reckitt Benckiser’s terse regulatory amendment raises questions about ESG disclosure, compliance costs and investor perception – explore the potential impact.

Estée Lauder expands distribution via a SalonCentric partnership, boosting physical and digital presence for Bumble & Bumble while keeping existing salon ties.

Explore why L’Oréal’s shares dipped 0.5% on January 26: a deep dive into its revenue growth, margin trends, regulatory risks, and long‑term value prospects for investors.

Kimberly‑Clark’s Q4 2025 earnings show EPS growth amid modest revenue decline; cost‑cutting, supply‑chain upgrades and eco‑innovation offer upside while private‑label pressure and regulatory risk loom.

Estée Lauder (EL) gains analyst upgrades, strong skin‑care growth and a disciplined capital strategy, but faces margin, supply‑chain and regulatory risks.

Institutional investors boost Colgate‑Palmolive shares, underscoring its steady dividend, robust product mix, and resilience in consumer staples markets.